Clinical Trial Update: A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of Elexacaftor/Tezacaftor/Ivacaftor in children aged 6-11 with Cystic Fibrosis has completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Elexacaftor-Tezacaftor-Ivacaftor (elexacaftor; tezacaftor; ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2022-07-26